To track your gifted subscription, go to your Account Settings 
We’ve emailed your gift link. Want us to send some more?
0 of 0 Subscription available
Not now, thanks
FILTERS
From Bessemer to Blume, investors can’t help being drawn to entrepreneurs with a not-so-storied past
MakeO’s aligners promise perfect smiles at a fraction of the usual price—but behind the Instagram gloss lie surprise charges, FDA claims, and a $270 million valuation in freefall
The diagnostics industry is transforming post-Covid, favouring blood-sample collections at your doorsteps. Yet, the reliability hinges on the journey your sample undertakes
Once IPO-bound and valued at over US$5 billion, the healthtech is now a tale of dubious business practices
The reported 90% cut in the valuation of Pharmeasy is a temporary exercise to help later investors and to find a place for the healthtech in the Manipal Group universe, an earlier investor which exited in less than a year in 2021
Business models are what enable companies to generate revenues and profits. Which ones are investors most interested in?
Relentless acquisitions, 24 loans, and an IPO U-turn later, the healthtech startup has found itself in a dicey situation. Justifying its valuation while raising funds to take on Tata-1mg and Reliance-backed Netmeds will be a hard sell
Healthtech startup Medibuddy saw its valuation shoot up 2.5X after raising $125 million in its latest funding round. The largely B2B player is now training its eyes to the rural B2C segment, but it has to figure out a way around the price-sensitive market
A delayed fund-raise, a perceived valuation competition with IPO-bound PharmEasy, a slew of oddball associations—Apollo’s digital health play is as complex as it is ambitious
India wants to digitise its healthcare system with a UPI-like system called Unified Health Interface. But between eclipsing the country’s flagship health programme PM-JAY and generating over 127 million health IDs without consent, UHI’s short history is quite checkered
After 26 years building HDFC Bank into India’s largest private bank, Aditya Puri has now turned his gaze (and riches) to pharma and healthcare. From IPO-bound Pharmeasy to Strides Group, can Puri’s Midas touch go beyond banking?
The Jenga tower of acquisitions at PharmEasy seems to be just that—precariously stacked to look tall. Integrating them in any meaningful way is not for the faint-hearted, nor is its upcoming $1 billion IPO, where it desires to be valued at $8-9 billion
Despite being India’s second largest pharma chain, MedPlus has struggled for both funding and valuations over its 15-year existence. With its slow and steady approach, will public markets give it the love it believes it deserves?
Mumbai-based diagnostics major Metropolis Healthcare was all set to swoop in and buy Chennai-based Dr Ganesan’s Hitech Diagnostic Centre in January. But then came the deal of all share swap deals from Indian diagnostics. How are Metropolis and others now going to play catch up to PE-rich PharmEasy?
Already struggling offline pharmacists had to deal with deep discounts online luring customers away. Now with corporates wanting to have the e-pharmacy cake and eat it too, offline pharma is banking on its intimate relationships with customers for an omnichannel experiment
Like with e-commerce, the game now shifts from startups to corporations
In two years, Hindi healthcare platform myUpchar went from a million page views a month to 12 million. Now, it’s building a healthcare delivery business for rural India—the market everyone aspiring to be a pan-Indian player has to crack
Every time Tata Group—one of India’s oldest conglomerates—plans to launch something, it spends a lot of time in testing waters. But despite being in four-year testing phase, Tata's digital health endeavour, Tata Health, has managed to make up 11.31% of Tata Industries Limited's turnover. It's now got a fair few hurdles to jump
In demerging its pharmacy business, Apollo Hospitals is splitting the ownership multiple ways. As baffling as it is, the endgame is not very hard to guess. It’s also one that could benefit one shareholding group more than the others
Rumour has it that Naspers, SoftBank and Temasek, all want to invest in the Indian e-pharmacy PharmEasy. $100 million or more. Because PharmEasy mirrors one of the oldest and the largest e-pharmacies in the world—111 Inc. But following 111 Inc all the way may not be the best idea, and other Indian e-pharmacies have made a mental note of it
After years of battling state regulators, proposed new legislation has ensured that e-pharmacies can look forward rather than over their shoulders
By continuing, you agree to our Terms of Service and Privacy Policy
“There's no greater gift than thinking that you had some impact on the world, for the better.”
– Gloria Steinem
Our anti-piracy system has flagged your account for suspicious activity and has temporarily paused your account. This may happen due to a number of reasons.
If you think that this was done in error, please get in touch with us at [email protected].
